A Retrospective Real-World Study Based on RATIONALE-307
Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
109 participants
Feb 28, 2026
OBSERVATIONAL
Conditions
Summary
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Eligibility
Inclusion Criteria1
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Exclusion Criteria1
- Patients who had a documented death before study completion in the RATIONALE-307 trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07478809